MetaCap

AnaptysBio (ANAB) vs Sarepta Therapeutics (SRPT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AnaptysBio (ANAB) has outperformed Sarepta Therapeutics (SRPT) over the past year, gaining 76.6% versus a loss of 24.6%. Over five years, ANAB leads with a +124.8% price change compared with -83.3% for SRPT. Sarepta Therapeutics is the larger company by market cap ($1.43 billion vs $1.39 billion), about 1.0 times the size, while AnaptysBio is growing revenue faster (+157.0% vs +15.6%).

On valuation, AnaptysBio trades at a lower forward P/E (8.7x vs 8.9x for Sarepta Therapeutics). AnaptysBio converts more of its revenue into profit, with a net margin of -5.6% versus -32.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANAB+76.58%SRPT-24.65%
+174%+70%-34%
Nov 21, 20251 yearNov 20, 2026
ANAB+127.09%SRPT-83.34%
+254%+76%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANAB versus SRPT key metrics
MetricANABSRPT
Share price$46.63$13.33
Market cap$1.39B$1.43B
1-day change-1.62%-5.93%
YTD return+44.28%-38.06%
1-year return+76.58%-24.65%
5-year return+124.76%-83.26%
P/E ratio (TTM)7.15666.50
Forward P/E8.668.87
EPS (TTM)$6.52$0.02
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$234.60M$2.20B
Revenue growth (YoY)+157.01%+15.58%
Net income (latest FY)$-13.23M$-713.41M
Gross margin—98.84%
Operating margin96.72%-31.83%
Net margin-5.64%-32.45%
52-week high$72.36$24.68
52-week low$26.01$13.25
Distance from 52-week high-35.56%-45.99%
Analyst consensusstrong_buyhold
Avg. price target upside+87.11%+63.32%
Average volume496.92K2.70M
Shares outstanding29.73M107.24M
Employees—835
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ANAB has outperformed SRPT by 101.2 percentage points over the past year.
  • Sarepta Therapeutics trades at a higher earnings multiple (666.5x vs 7.2x trailing P/E).
  • AnaptysBio is more profitable, keeping -5.6 cents of every revenue dollar as net income versus -32.5 cents for Sarepta Therapeutics.
  • AnaptysBio grew revenue faster in its latest fiscal year (+157.01% vs +15.58%).

About AnaptysBio

ANAB stock →

AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations

About Sarepta Therapeutics

SRPT stock →

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.

Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees

ANAB vs SRPT FAQ

Which is bigger, AnaptysBio or Sarepta Therapeutics?

Sarepta Therapeutics (SRPT) is larger, with a market capitalization of $1.43B compared with $1.39B for AnaptysBio (ANAB).

Which stock has performed better over the past year, ANAB or SRPT?

ANAB returned +76.58% over the past 12 months, compared with -24.65% for SRPT (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, ANAB or SRPT?

ANAB has the lower trailing P/E at 7.2, versus 666.5 for SRPT. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are AnaptysBio and Sarepta Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons